Advantage Alpha Capital Partners LP Reduces Position in Dynavax Technologies Corporation $DVAX

Advantage Alpha Capital Partners LP trimmed its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 19.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 31,158 shares of the biopharmaceutical company’s stock after selling 7,285 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Dynavax Technologies were worth $309,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of DVAX. Jacobs Levy Equity Management Inc. purchased a new position in shares of Dynavax Technologies during the 1st quarter valued at about $2,477,000. Woodline Partners LP raised its stake in Dynavax Technologies by 48.4% during the 1st quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company’s stock worth $15,289,000 after acquiring an additional 384,288 shares during the period. Exchange Traded Concepts LLC lifted its holdings in Dynavax Technologies by 4.3% during the second quarter. Exchange Traded Concepts LLC now owns 133,601 shares of the biopharmaceutical company’s stock valued at $1,325,000 after purchasing an additional 5,523 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Dynavax Technologies in the second quarter worth approximately $1,381,000. Finally, Peregrine Capital Management LLC increased its stake in shares of Dynavax Technologies by 1.8% in the second quarter. Peregrine Capital Management LLC now owns 688,896 shares of the biopharmaceutical company’s stock worth $6,834,000 after purchasing an additional 11,878 shares in the last quarter. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Stock Down 0.5%

DVAX opened at $11.37 on Friday. The company has a market capitalization of $1.34 billion, a PE ratio of -24.72 and a beta of 1.09. The firm has a 50-day simple moving average of $10.45 and a two-hundred day simple moving average of $10.34. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45. Dynavax Technologies Corporation has a 52 week low of $9.20 and a 52 week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The firm had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million. Analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on DVAX. JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of Dynavax Technologies in a research note on Friday, August 22nd. Wall Street Zen upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.